306 related articles for article (PubMed ID: 23934049)
1. Structures of human folate receptors reveal biological trafficking states and diversity in folate and antifolate recognition.
Wibowo AS; Singh M; Reeder KM; Carter JJ; Kovach AR; Meng W; Ratnam M; Zhang F; Dann CE
Proc Natl Acad Sci U S A; 2013 Sep; 110(38):15180-8. PubMed ID: 23934049
[TBL] [Abstract][Full Text] [Related]
2. The role of alpha-folate receptor-mediated transport in the antitumor activity of antifolate drugs.
Theti DS; Jackman AL
Clin Cancer Res; 2004 Feb; 10(3):1080-9. PubMed ID: 14871988
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry.
Deng Y; Zhou X; Kugel Desmoulin S; Wu J; Cherian C; Hou Z; Matherly LH; Gangjee A
J Med Chem; 2009 May; 52(9):2940-51. PubMed ID: 19371039
[TBL] [Abstract][Full Text] [Related]
4. The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis.
Assaraf YG
Drug Resist Updat; 2006; 9(4-5):227-46. PubMed ID: 17092765
[TBL] [Abstract][Full Text] [Related]
5. Functional aspects of membrane folate receptors in human breast cancer cells with transport-related resistance to methotrexate.
Pinard MF; Jolivet J; Ratnam M; Kathmann I; Molthoff C; Westerhof R; Schornagel JH; Jansen G
Cancer Chemother Pharmacol; 1996; 38(3):281-8. PubMed ID: 8646804
[TBL] [Abstract][Full Text] [Related]
6. Structural and Enzymatic Analysis of Tumor-Targeted Antifolates That Inhibit Glycinamide Ribonucleotide Formyltransferase.
Deis SM; Doshi A; Hou Z; Matherly LH; Gangjee A; Dann CE
Biochemistry; 2016 Aug; 55(32):4574-82. PubMed ID: 27439469
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of novel pyrrolo[2,3-d]pyrimidine as tumor-targeting agents with selectivity for tumor uptake by high affinity folate receptors over the reduced folate carrier.
Golani LK; Islam F; O'Connor C; Dekhne AS; Hou Z; Matherly LH; Gangjee A
Bioorg Med Chem; 2020 Jun; 28(12):115544. PubMed ID: 32503687
[TBL] [Abstract][Full Text] [Related]
8. The antifolates: evolution, new agents in the clinic, and how targeting delivery via specific membrane transporters is driving the development of a next generation of folate analogs.
Goldman ID; Chattopadhyay S; Zhao R; Moran R
Curr Opin Investig Drugs; 2010 Dec; 11(12):1409-23. PubMed ID: 21154123
[TBL] [Abstract][Full Text] [Related]
9. Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance.
Gonen N; Assaraf YG
Drug Resist Updat; 2012 Aug; 15(4):183-210. PubMed ID: 22921318
[TBL] [Abstract][Full Text] [Related]
10. Regulation of carrier-mediated transport of folates and antifolates in methotrexate-sensitive and-resistant leukemia cells.
Jansen G; Mauritz RM; Assaraf YG; Sprecher H; Drori S; Kathmann I; Westerhof GR; Priest DG; Bunni M; Pinedo HM; Schornagel JH; Peters GJ
Adv Enzyme Regul; 1997; 37():59-76. PubMed ID: 9381986
[TBL] [Abstract][Full Text] [Related]
11. Structural basis for recognition and transport of folic acid in mammalian cells.
Newstead S
Curr Opin Struct Biol; 2022 Jun; 74():102353. PubMed ID: 35303537
[TBL] [Abstract][Full Text] [Related]
12. Folate coenzyme and antifolate transport proteins in normal and neoplastic cells.
Freisheim JH; Price EM; Ratnam M
Adv Enzyme Regul; 1989; 29():13-26. PubMed ID: 2561247
[TBL] [Abstract][Full Text] [Related]
13. Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines.
Liani E; Rothem L; Bunni MA; Smith CA; Jansen G; Assaraf YG
Int J Cancer; 2003 Feb; 103(5):587-99. PubMed ID: 12494465
[TBL] [Abstract][Full Text] [Related]
14. Anticancer antifolates: current status and future directions.
McGuire JJ
Curr Pharm Des; 2003; 9(31):2593-613. PubMed ID: 14529544
[TBL] [Abstract][Full Text] [Related]
15. Internalization of Methotrexate Conjugates by Folate Receptor-α.
Nogueira E; Sárria MP; Azoia NG; Antunes E; Loureiro A; Guimarães D; Noro J; Rollett A; Guebitz G; Cavaco-Paulo A
Biochemistry; 2018 Dec; 57(49):6780-6786. PubMed ID: 30452231
[TBL] [Abstract][Full Text] [Related]
16. Altered transport of folic acid and antifolates through the carrier mediated reduced folate transport system in a human leukemia cell line resistant to (6R) 5,10-dideazatetrahydrofolic acid (DDATHF).
Pavlovic M; Leffert JJ; Russello O; Bunni MA; Beardsley GP; Priest DG; Pizzorno G
Adv Exp Med Biol; 1993; 338():775-8. PubMed ID: 8304227
[No Abstract] [Full Text] [Related]
17. Folate transport and the modulation of antifolate sensitivity in a methotrexate-resistant human breast cancer cell line.
Dixon KH; Trepel JB; Eng SC; Cowan KH
Cancer Commun; 1991; 3(12):357-65. PubMed ID: 16296001
[TBL] [Abstract][Full Text] [Related]
18. Characterization of binding of folates and antifolates to brush-border membrane vesicles isolated from human kidney.
Damaraju VL; Hamilton KF; Seth-Smith ML; Cass CE; Sawyer MB
Mol Pharmacol; 2005 Feb; 67(2):453-9. PubMed ID: 15509714
[TBL] [Abstract][Full Text] [Related]
19. Arabinogalactan-folic acid-drug conjugate for targeted delivery and target-activated release of anticancer drugs to folate receptor-overexpressing cells.
Pinhassi RI; Assaraf YG; Farber S; Stark M; Ickowicz D; Drori S; Domb AJ; Livney YD
Biomacromolecules; 2010 Jan; 11(1):294-303. PubMed ID: 20014825
[TBL] [Abstract][Full Text] [Related]
20. The folate receptor as a rational therapeutic target for personalized cancer treatment.
Assaraf YG; Leamon CP; Reddy JA
Drug Resist Updat; 2014; 17(4-6):89-95. PubMed ID: 25457975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
